Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 1710.10% is 56% below its 5-year average of 3928.40%, near the high end of its 5-year range (-237675.43%–30475.05%).
101.44% above its 12-month average of -118386.57%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2020 (2020-12-31): -237675.43%.
EBITDA MARGIN
1710.10%
EBITDA MARGIN AVG TTM
-118386.57%
EBITDA MARGIN AVG 3Y
-32768.40%
EBITDA MARGIN AVG 5Y
3928.40%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+101.44%
CURRENT VS 3Y AVG
+105.22%
CURRENT VS 5Y AVG
-56.47%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GlucoTrack, Inc.
Market Cap
$885939.00
EBITDA Margin
1710.10%
TTM Avg
-118386.57%
3Y Avg
-32768.40%
5Y Avg
3928.40%
Market Cap
$888387.00
EBITDA Margin
-148.44%
TTM Avg
-191.64%
3Y Avg
-1422.24%
5Y Avg
-1921.61%
Market Cap
$878396.00
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$787624.00
EBITDA Margin
-3618.46%
TTM Avg
-3618.46%
3Y Avg
-3618.46%
5Y Avg
-3618.46%
Market Cap
$1.02M
EBITDA Margin
-182712.72%
TTM Avg
-182712.72%
3Y Avg
-182712.72%
5Y Avg
-182712.72%
Market Cap
$1.14M
EBITDA Margin
-6.76%
TTM Avg
-0.42%
3Y Avg
7.09%
5Y Avg
7.09%
Market Cap
$1.17M
EBITDA Margin
-17.60%
TTM Avg
-16.25%
3Y Avg
-23.94%
5Y Avg
-32.10%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GlucoTrack, Inc. (GCTK) | $885939.00 | 1710.10% | -118386.57% | -32768.40% | 3928.40% |
| Decoy Therapeutics Inc. (DCOY)vs › | $888387.00 | -148.44% | -191.64% | -1422.24% | -1921.61% |
| Bone Biologics Corporation (BBLG)vs › | $878396.00 | N/A | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $787624.00 | -3618.46% | -3618.46% | -3618.46% | -3618.46% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | -182712.72% | -182712.72% | -182712.72% | -182712.72% |
| CDT Equity Inc. (CDT)vs › | $707297.00 | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.11M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.14M | -6.76% | -0.42% | 7.09% | 7.09% |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | -17.60% | -16.25% | -23.94% | -32.10% |
| HCW Biologics Inc. (HCWB)vs › | $570131.00 | -18836.70% | -9969.53% | -5254.43% | -4229.16% |
Gross Margin
0.0%
EBITDA Margin
1710.1%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2020-12-31 | -237675.43% |
| 2019-12-31 | 902.29% |
| 2019-09-30 | -23196.96% |
| 2019-06-30 | -797.67% |
| 2019-03-31 | 4062.95% |
| 2018-06-30 | -12851.66% |
| 2018-03-31 | 6827.42% |
| 2017-12-31 | 581.85% |
| 2017-09-30 | 12754.44% |
| 2017-06-30 | 30475.05% |
| 2017-03-31 | 2718.27% |
| 2016-12-31 | 1034.12% |
| 2016-09-30 | 13278.20% |
| 2016-06-30 | 419.07% |
| 2016-03-31 | 1431.46% |
| 2015-06-30 | 1642.05% |
| 2015-03-31 | 1173.05% |
| 2014-12-31 | 3128.65% |
| 2014-09-30 | -3007.10% |
